Oral golcadomide with rituximab delivers high responses and manageable safety, enabling outpatient care for relapsed follicular lymphoma.
Daniel Morillo, MD
Advertisement
Articles by Daniel Morillo, MD
Golcadomide plus rituximab shows deep, durable responses in relapsed follicular lymphoma, with manageable neutropenia and limited added toxicity.
Advertisement
Latest Updated Articles
Oral CELMoD Golcadomide Advances in Relapsed FLJuly 8th 2026
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Platinum/Pemetrexed Active in Mesothelioma After First-Line Immunotherapy
2
Oncologists Weigh Frontline BTK Inhibitor Strategies in CLL
3
mRNA Vaccine Plus Pembrolizumab Yields RFS, DMFS Benefit in Resectable Melanoma
4
Immune Profiling Could Optimize T-Cell Therapy in Relapsed Myeloma
5